JW Lifescience Corporation

KSE 234080.KS

JW Lifescience Corporation Free Cash Flow Yield on February 03, 2025: 20.09%

JW Lifescience Corporation Free Cash Flow Yield is 20.09% on February 03, 2025, a 30.25% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

JW Lifescience Corporation 52-week high Free Cash Flow Yield is 20.09% on February 03, 2025, which is 0.00% below the current Free Cash Flow Yield.
JW Lifescience Corporation 52-week low Free Cash Flow Yield is 14.65% on February 22, 2024, which is -27.11% below the current Free Cash Flow Yield.
JW Lifescience Corporation average Free Cash Flow Yield for the last 52 weeks is 17.17%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

KSE: 234080.KS

JW Lifescience Corporation

CEO	Sungnam Cha
IPO Date	Oct. 27, 2016
Location	South Korea
Headquarters	28, Hanjin 1-gil
Employees	301
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Baby & Childcare Biotechnology Frozen Foods Personal Care Pet Food Pharmaceuticals Soft Drinks & Sodas

Description

JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.

Key trends

Past 5 years